Summit DMD Data Intrigue But Longer-Term Results Awaited
Executive Summary
Early data for ezutromid in Duchenne muscular dystrophy product give some proof of concept as a broad treatment for the fatal genetic disease – more data are awaited as Summit steps up its pivotal trial plans.
You may also be interested in...
In DMD, Summit Falls Well Short Of Peak It Hoped For
Summit’s utrophin modulator, ezutromid, posted intriguing interim data in January, but failed to meet the primary and all secondary endpoints in a Phase II study. The UK firm discontinued development of ezutromid and will now focus on novel antibiotic candidates.
Santhera Braced For Another CHMP No In Duchenne
Santhera had a tumultuous 2017 and recovery is not going to be easy this year as its lead compound for the rare disease Duchenne muscular dystrophy is about to be rejected by regulators in Europe for a second time.
Sarepta’s $852m Summit Collaboration Could Enable DMD Drug Combinations
Sarepta committed up to $562m for European and other rights to Summit’s lead DMD drug candidate ezutromid plus additional fees for other utrophin modulators in a deal announced on Oct. 4 that could enable combination therapy regimens.